Literature DB >> 10951144

IgG, IgA and IgE autoantibodies against the ectodomain of BP180 in patients with bullous and cicatricial pemphigoid and linear IgA bullous dermatosis.

S Christophoridis1, L Büdinger, L Borradori, T Hunziker, H F Merk, M Hertl.   

Abstract

BACKGROUND: Bullous pemphigoid (BP), linear IgA bullous dermatosis (LABD) and cicatricial pemphigoid (CP) are clinically distinct autoimmune bullous skin diseases characterized by autoantibodies against components of the epidermal basement membrane. Like most patients with BP, a significant subgroup of patients with CP has circulating IgG specific for BP180, a transmembraneous protein of hemidesmosomes. Moreover, sera of patients with LABD contain IgA autoantibodies reactive with a 97/120-kDa protein, LABD antigen 1, which is highly homologous to the extracellular portion of BP180.
OBJECTIVES: We aimed to determine whether, in these diseases, autoantibody reactivity to BP180 is restricted to distinct immunoglobulin subtypes.
METHODS: Utilizing a baculovirus-encoded form of the ectodomain of BP180, sera from patients with BP (n = 10), CP (n = 9), LABD (n = 10) and normal human control sera (n = 10) were analysed by immunoblot for IgG, IgA and IgE reactivity against BP180.
RESULTS: All of 10 BP sera displayed IgG, IgA and IgE reactivity with BP180. Six and seven of nine CP sera, respectively, contained IgG and IgA autoantibodies reactive with BP180, but none of nine sera contained BP180-specific IgE. Nine of 10 LABD sera contained IgA, and six of 10 IgG, which was reactive with BP180, but none of 10 sera showed IgE reactivity to BP180.
CONCLUSIONS: The presence of IgG and IgA autoantibody responses to BP180 in patients with three clinically distinct autoimmune bullous diseases indicates that an autoimmune response to the same distinct adhesion protein may lead to different clinical manifestations. It is therefore conceivable that variable epitopes of BP180 are targeted by the different autoantibody isotypes, resulting in the distinct clinical pictures.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10951144     DOI: 10.1046/j.1365-2133.2000.03661.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  16 in total

Review 1.  Non-infectious environmental antigens as a trigger for the initiation of an autoimmune skin disease.

Authors:  Ye Qian; Donna A Culton; Joseph S Jeong; Nicole Trupiano; Jesus G Valenzuela; Luis A Diaz
Journal:  Autoimmun Rev       Date:  2016-07-08       Impact factor: 9.754

Review 2.  Targeted Therapies for Autoimmune Bullous Diseases: Current Status.

Authors:  Kyle T Amber; Roberto Maglie; Farzan Solimani; Rüdiger Eming; Michael Hertl
Journal:  Drugs       Date:  2018-10       Impact factor: 9.546

Review 3.  Unraveling the significance of IgE autoantibodies in organ-specific autoimmunity: lessons learned from bullous pemphigoid.

Authors:  K A N Messingham; H M Holahan; J A Fairley
Journal:  Immunol Res       Date:  2014-08       Impact factor: 2.829

4.  A novel ELISA reveals high frequencies of BP180-specific IgE production in bullous pemphigoid.

Authors:  Kelly A N Messingham; Megan H Noe; Marisa A Chapman; George J Giudice; Janet A Fairley
Journal:  J Immunol Methods       Date:  2009-05-05       Impact factor: 2.303

5.  Serological diagnosis of autoimmune bullous skin diseases: prospective comparison of the BIOCHIP mosaic-based indirect immunofluorescence technique with the conventional multi-step single test strategy.

Authors:  Nina van Beek; Kristin Rentzsch; Christian Probst; Lars Komorowski; Michael Kasperkiewicz; Kai Fechner; Inga M Bloecker; Detlef Zillikens; Winfried Stöcker; Enno Schmidt
Journal:  Orphanet J Rare Dis       Date:  2012-08-09       Impact factor: 4.123

6.  Omalizumab therapy for bullous pemphigoid.

Authors:  Kenneth K Yu; Ashley B Crew; Kelly A N Messingham; Janet A Fairley; David T Woodley
Journal:  J Am Acad Dermatol       Date:  2014-06-20       Impact factor: 15.487

Review 7.  BP180 Is Critical in the Autoimmunity of Bullous Pemphigoid.

Authors:  Yale Liu; Liang Li; Yumin Xia
Journal:  Front Immunol       Date:  2017-12-08       Impact factor: 7.561

Review 8.  Immunoglobulin E-Mediated Autoimmunity.

Authors:  Marcus Maurer; Sabine Altrichter; Oliver Schmetzer; Jörg Scheffel; Martin K Church; Martin Metz
Journal:  Front Immunol       Date:  2018-04-09       Impact factor: 7.561

9.  IgE autoreactivity in bullous pemphigoid: eosinophils and mast cells as major targets of pathogenic immune reactants.

Authors:  P C Freire; C H Muñoz; G Stingl
Journal:  Br J Dermatol       Date:  2017-11-28       Impact factor: 9.302

Review 10.  Humoral Epitope Spreading in Autoimmune Bullous Diseases.

Authors:  Dario Didona; Giovanni Di Zenzo
Journal:  Front Immunol       Date:  2018-04-17       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.